Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
Add more filters










Publication year range
1.
J Neuroinflammation ; 18(1): 39, 2021 Feb 02.
Article in English | MEDLINE | ID: mdl-33531028

ABSTRACT

BACKGROUND: Bacterial meningitis is a fatal disease with a mortality up to 30% and neurological sequelae in one fourth of survivors. Available vaccines do not fully protect against this lethal disease. Here, we report the protective effect of synthetic oligodeoxynucleotides containing unmethylated cytosine-guanine motifs (CpG ODN) against the most frequent form of bacterial meningitis caused by Streptococcus pneumoniae. METHODS: Three days prior to the induction of meningitis by intracerebral injection of S. pneumoniae D39, wild-type and Toll-like receptor (TLR9)-/- mice received an intraperitoneal injection of 100 µg CpG ODN or vehicle. To render mice neutropenic, anti-Ly-6G monoclonal antibody was daily administrated starting 4 days before infection with a total of 7 injections. Kaplan-Meier survival analyses and bacteriological studies, in which mice were sacrificed 24 h and 36 h after infection, were performed. RESULTS: Pre-treatment with 100 µg CpG ODN prolonged survival of immunocompetent and neutropenic wild-type mice but not of TLR9-/- mice. There was a trend towards lower mortality in CpG ODN-treated immunocompetent and neutropenic wild-type mice. CpG ODN caused an increase of IL-12/IL-23p40 levels in the spleen and serum in uninfected animals. The effects of CpG ODN on bacterial concentrations and development of clinical symptoms were associated with an increased number of microglia in the CNS during the early phase of infection. Elevated concentrations of IL-12/IL-23p40 and MIP-1α correlated with lower bacterial concentrations in the blood and spleen during infection. CONCLUSIONS: Pre-conditioning with CpG ODN strengthened the resistance of neutropenic and immunocompetent mice against S. pneumoniae meningitis in the presence of TLR9. Administration of CpG ODN decreased bacterial burden in the cerebellum and reduced the degree of bacteremia. Systemic administration of CpG ODN may help to prevent or slow the progression to sepsis of bacterial CNS infections in healthy and immunocompromised individuals even after direct inoculation of bacteria into the intracranial compartments, which can occur after sinusitis, mastoiditis, open head trauma, and surgery, including placement of an external ventricular drain.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Immunocompetence/immunology , Immunocompromised Host/immunology , Meningitis, Pneumococcal/immunology , Neutropenia/immunology , Oligodeoxyribonucleotides/administration & dosage , Animals , Cerebellum/drug effects , Cerebellum/immunology , Cerebellum/metabolism , Female , Immunocompetence/drug effects , Immunocompromised Host/drug effects , Injections, Intraventricular , Male , Meningitis, Pneumococcal/drug therapy , Meningitis, Pneumococcal/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Neutropenia/metabolism , Neutropenia/prevention & control , Spleen/drug effects , Spleen/immunology , Spleen/metabolism , Streptococcus pneumoniae , Treatment Outcome
2.
Brain Behav Immun ; 48: 205-21, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25843371

ABSTRACT

Microglia, the innate immune cells of the central nervous system (CNS), react to endotoxins like bacterial lipopolysaccharides (LPS) with a pronounced inflammatory response. To avoid excess damage to the CNS, the microglia inflammatory response needs to be tightly regulated. Here we report that a single LPS challenge results in a prolonged blunted pro-inflammatory response to a subsequent LPS stimulation, both in primary microglia cultures (100 ng/ml) and in vivo after intraperitoneal (0.25 and 1mg/kg) or intracerebroventricular (5 µg) LPS administration. Chromatin immunoprecipitation (ChIP) experiments with primary microglia and microglia acutely isolated from mice showed that LPS preconditioning was accompanied by a reduction in active histone modifications AcH3 and H3K4me3 in the promoters of the IL-1ß and TNF-α genes. Furthermore, LPS preconditioning resulted in an increase in the amount of repressive histone modification H3K9me2 in the IL-1ß promoter. ChIP and knock-down experiments showed that NF-κB subunit RelB was bound to the IL-1ß promoter in preconditioned microglia and that RelB is required for the attenuated LPS response. In addition to a suppressed pro-inflammatory response, preconditioned primary microglia displayed enhanced phagocytic activity, increased outward potassium currents and nitric oxide production in response to a second LPS challenge. In vivo, a single i.p. LPS injection resulted in reduced performance in a spatial learning task 4 weeks later, indicating that a single inflammatory episode affected memory formation in these mice. Summarizing, we show that LPS-preconditioned microglia acquire an epigenetically regulated, immune-suppressed phenotype, possibly to prevent excessive damage to the central nervous system in case of recurrent (peripheral) inflammation.


Subject(s)
Epigenesis, Genetic , Gene Silencing , Lipopolysaccharides/pharmacology , Microglia/metabolism , Transcription Factor RelB/metabolism , Animals , Histones/metabolism , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Mice , Microglia/drug effects , NF-kappa B/genetics , NF-kappa B/metabolism , Promoter Regions, Genetic , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
3.
J Neuroimmune Pharmacol ; 8(4): 807-23, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23881706

ABSTRACT

Microglia are the prime innate immune cells of the central nervous system. They can transit from a (so-called) resting state under homeostatic conditions towards a pro-inflammatory activation state upon homeostatic disturbances. Under neurodegenerative conditions, microglia have been largely perceived as neurotoxic cells. It is now becoming clear that resting microglia are not inactive but that they serve house-keeping functions. Moreover, microglia activity is not limited to proinflammatory responses, but covers a spectrum of reactive profiles. Depending on the actual situation, activated microglia display specific effector functions supporting inflammation, tissue remodeling, synaptic plasticity and neurogenesis. Many of these functions not only relate to the current state of the local neural environment but also depend on previous experience. In this review, we address microglia functions with respect to determining factors, phenotypic presentations, adaptation to environmental signals and aging. Finally, we point out primary mechanisms of microglia activation, which may comprise therapeutic targets to control neuro-inflammatory and neurodegenerative activity.


Subject(s)
Adaptation, Physiological , Microglia/physiology , Phenotype , Adaptation, Physiological/genetics , Adaptation, Physiological/immunology , Aging/genetics , Aging/immunology , Aging/pathology , Animals , Humans , Microglia/immunology , Microglia/pathology , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/pathology
4.
Neuroreport ; 12(11): 2513-7, 2001 Aug 08.
Article in English | MEDLINE | ID: mdl-11496140

ABSTRACT

Astrocytes induce blood-brain barrier (BBB) properties in brain endothelial cells (EC)*O(2)*, generated in blood and EC, opens the BBB. Hence, high activity of superoxide dismutase (SOD) is a prerequisite for normal BBB function. Therefore, the influence of rat astrocytes on the expression of manganese (Mn)SOD in rat EC was investigated in two coculture models of the BBB, allowing either exchange of soluble factors or additionally cellular contacts. Activity, protein content and mRNA expression of endothelial MnSOD were significantly increased in both coculture models in comparison to monoculture by soluble astrocytic factors, such as cytokines. High activity of endothelial MnSOD may be considered as a further essential property of the BBB, which is induced and maintained by astrocytes.


Subject(s)
Astrocytes/metabolism , Endothelium, Vascular/enzymology , Superoxide Dismutase/metabolism , Animals , Astrocytes/cytology , Blood-Brain Barrier/physiology , Brain/cytology , Cell Line, Transformed , Coculture Techniques , Endothelium, Vascular/cytology , Free Radicals/metabolism , Gene Expression Regulation, Enzymologic , Interleukin-1/metabolism , RNA, Messenger/analysis , Rats , Superoxide Dismutase/genetics , Tumor Necrosis Factor-alpha/metabolism
5.
Eur J Immunol ; 31(7): 2104-15, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11449364

ABSTRACT

Central nervous system (CNS) infections caused by Streptococcus pneumoniae still have a disastrous outcome. Underlying immunological and CNS cellular events are largely enigmatic. We used pneumococcal cells walls (PCW) to investigate microglial responses as these cells are prominent sensors and effectors during neuropathological changes. PCW stimulation of mouse microglia in vitro evoked the release of the cyto- and chemokines, TNF-alpha, IL-6, IL-12, KC, MCP-1, MIP-1alpha, MIP-2 and RANTES as well as soluble TNF receptor II, a potential TNF-alpha antagonist. The release induction followed extremely steep dose-response relations, and short exposure periods (15 min) were already sufficient to trigger substantial responses. PCW signaling controlling the release depended on both p38 and p42/p44 (ERK2/ERK1) MAP kinase activities. The kinase inhibitor, tyrphostin AG126 prevented the PCW-inducible phosphorylation of p42/p44(MAPK), potently blocked cytokine release and drastically reduced the bioavailable TNF-alpha, since it only marginally affected the release of soluble TNF receptors. Moreover, in an in vivo model of pneumococcal meningitis, AG126 significantly attenuated the PCW-induced leukocyte influx to the cerebrospinal fluid. The findings imply that pneumococcal CNS infection can cause a rapid and massive microglial activation and that ERK/MAPK pathway(s) are potential targets for pharmacological interventions.


Subject(s)
Cytokines/biosynthesis , Enzyme Inhibitors/pharmacology , Meningitis, Pneumococcal/immunology , Microglia/immunology , Protein-Tyrosine Kinases/antagonists & inhibitors , Tyrphostins/pharmacology , Animals , Cell Wall/immunology , Cells, Cultured , Chemokines/biosynthesis , MAP Kinase Kinase 1 , MAP Kinase Kinase 2 , Male , Mice , Microglia/drug effects , Mitogen-Activated Protein Kinase 1/physiology , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/physiology , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/metabolism , Rats , Rats, Wistar , Receptors, Tumor Necrosis Factor/biosynthesis , Streptococcus pneumoniae/immunology , Tumor Necrosis Factor-alpha/biosynthesis , p38 Mitogen-Activated Protein Kinases
6.
J Comp Neurol ; 431(2): 217-27, 2001 Mar 05.
Article in English | MEDLINE | ID: mdl-11170001

ABSTRACT

An organotypic culture system of the early postnatal rat retina was developed to study microglial activation within a tissue environment. One day after tissue preparation, microglial cells of the ganglion cell/nerve fiber layer revealed features of activation. Cells acquired an ameboid morphology as revealed by Bandeiraea simplicifolia lectin staining. Proliferation-as revealed by Ki67 immunocytochemistry-resulted in higher cell densities. In the supernatant, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant factor-1 (MCP-1) were detected by using specific enzyme-linked immunosorbent assay systems, activated microglia being the most likely source of their release. After 6 days in vitro (div), microglial cells regained their resting morphology, and cell counts returned to control levels. Concomitantly, the release activity decreased to undetectable levels. When slices were treated at this later stage of cultivation (>6 div) with bacterial lipopolysaccharide (LPS; 100 ng/ml for 24 hours), microglial cells became activated, as revealed by a change in morphology. In parallel, the LPS treatment also resulted in high levels of TNF-alpha, IL-6, and MCP-1 in the culture medium. Both the release from the tissue and the morphological changes of the microglia were reversible. Seventy-two hours after LPS removal, only microglia with ramified morphology were found, and release activities returned to baseline. These data suggest that the organotypic culture of the retina is a useful model for studying microglial activation from its resting form.


Subject(s)
Cells, Cultured/cytology , Microglia/cytology , Models, Biological , Rats, Wistar/anatomy & histology , Retina/cytology , Animals , Animals, Newborn/anatomy & histology , Animals, Newborn/growth & development , Animals, Newborn/metabolism , Astrocytes/cytology , Astrocytes/metabolism , Capillaries/cytology , Capillaries/metabolism , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Division/drug effects , Cell Division/physiology , Cell Size/drug effects , Cell Size/physiology , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Chemokines/metabolism , Cytokines/metabolism , Ki-67 Antigen/metabolism , Lipopolysaccharides/pharmacology , Microglia/drug effects , Microglia/metabolism , Organ Culture Techniques , Rats , Rats, Wistar/growth & development , Rats, Wistar/metabolism , Retina/drug effects , Retina/metabolism , Retinal Ganglion Cells/cytology , Retinal Ganglion Cells/metabolism , Time Factors
7.
Glia ; 33(1): 72-86, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11169793

ABSTRACT

We have generated transgenic mice in which astrocytes are labeled by the enhanced green fluorescent protein (EGFP) under the control of the human glial fibrillary acidic protein (GFAP) promoter. In all regions of the CNS, such as cortex, cerebellum, striatum, corpus callosum, hippocampus, retina, and spinal cord, EGFP-positive cells with morphological properties of astrocytes could be readily visualized by direct fluorescence microscopy in living brain slices or whole mounts. Also in the PNS, nonmyelinating Schwann cells from the sciatic nerve could be identified by their bright green fluorescence. Highest EGFP expression was found in the cerebellum. Already in acutely prepared whole brain, the cerebellum appeared green-yellowish under normal daylight. Colabeling with GFAP antibodies revealed an overlap with EGFP in the majority of cells. Some brain areas, however, such as retina or hypothalamus, showed only low levels of EGFP expression, although the astrocytes were rich in GFAP. In contrast, some areas that were poor in immunoreactive GFAP were conspicuous for their EGFP expression. Applying the patch clamp technique in brain slices, EGFP-positive cells exhibited two types of membrane properties, a passive membrane conductance as described for astrocytes and voltage-gated channels as described for glial precursor cells. Electron microscopical investigation of ultrastructural properties revealed EGFP-positive cells enwrapping synapses by their fine membrane processes. EGFP-positive cells were negative for oligodendrocyte (MAG) and neuronal markers (NeuN). As response to injury, i.e., by cortical stab wounds, enhanced levels of EGFP expression delineated the lesion site and could thus be used as a live marker for pathology.


Subject(s)
Astrocytes/metabolism , Astrocytes/ultrastructure , Glial Fibrillary Acidic Protein/genetics , Luminescent Proteins/analysis , Luminescent Proteins/genetics , Mice, Transgenic/genetics , Promoter Regions, Genetic/physiology , Animals , Brain/metabolism , Brain/ultrastructure , Gene Expression Regulation/physiology , Glial Fibrillary Acidic Protein/metabolism , Gliosis/genetics , Gliosis/pathology , Green Fluorescent Proteins , Immunohistochemistry , Mice , Mice, Transgenic/anatomy & histology , Microscopy, Electron , Neurons/cytology , Neurons/metabolism , Oligodendroglia/cytology , Oligodendroglia/metabolism , Peripheral Nerves/metabolism , Peripheral Nerves/ultrastructure
8.
J Neurochem ; 75(4): 1539-47, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10987834

ABSTRACT

Microglia are the resident immune cells of the CNS. Upon brain damage, these cells are rapidly activated and function as tissue macrophages. The first steps in this activation still remain unclear, but it is widely believed that substances released from damaged brain tissue trigger this process. In this article, we describe the effects of the blood coagulation factor thrombin on cultured rodent microglial cells. Thrombin induced a transient Ca(2+) increase in microglial cells, which persisted in Ca(2+)-free media. It was blocked by thapsigargin, indicating that thrombin caused a Ca(2+) release from internal stores. Preincubation with pertussis toxin did not alter the thrombin-induced [Ca(2+)](i) signal, whereas it was blocked by hirudin, a blocker of thrombin's proteolytic activity. Incubation with thrombin led to the production of nitric oxide and the release of the cytokines tumor necrosis factor-alpha, interleukin-6, interleukin-12, the chemokine KC, and the soluble tumor necrosis factor-alpha receptor II and had a significant proliferative effect. Our findings indicate that thrombin, a molecule that enters the brain at sites of injury, rapidly triggered microglial activation.


Subject(s)
Microglia/drug effects , Thrombin/pharmacology , Adenosine Triphosphate/metabolism , Adenosine Triphosphate/pharmacology , Animals , Antithrombins/pharmacology , Calcium Signaling/drug effects , Calcium-Transporting ATPases/antagonists & inhibitors , Cell Division/drug effects , Cells, Cultured , Chemokines/metabolism , Cytokines/metabolism , Dose-Response Relationship, Drug , GTP-Binding Proteins/antagonists & inhibitors , Hirudins/pharmacology , Intracellular Fluid/metabolism , Microglia/cytology , Microglia/metabolism , Nitric Oxide/metabolism , Pertussis Toxin , Rats , Rats, Long-Evans , Signal Transduction/drug effects , Thapsigargin/pharmacology , Thrombin/antagonists & inhibitors , Virulence Factors, Bordetella/pharmacology
9.
Glia ; 29(4): 355-65, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10652445

ABSTRACT

The 20S proteasome is a multicatalytic threonine protease and serves to process peptides that are subsequently presented as antigenic epitopes by MHC class I molecules. In the brain, microglial cells are the major antigen presenting cells and they respond sensitive to pathologic events. We used cultured mouse microglia and a microglial cell line, the BV-2 line, as a model to study the correlation between microglial activation parameters and structural plasticity of the 20S/26S proteasome. Lipopolysaccharide (LPS)- or interferon-gamma (IFN-gamma)-stimulated microglia or BV-2 cells exhibit properties of activated microglia such as high levels of TNFalpha and IL-6 release. In response to IFN-gamma or LPS, three constitutive beta subunits (beta1/Delta, beta2/MC14, beta5/MB1) were replaced by the immunoproteasome subunits ibeta1/LMP2, ibeta2/MECL-1, and ibeta5/LMP7, indicating that activated microglia adapts its proteasomal subunit composition to the requirements of an optimized MHC class I epitope processing. Induction of immunoproteasomes in BV-2 cells was solely provoked by IFN-gamma, but not by LPS. Moreover, LPS (but not IFN-gamma) triggered the expression of a novel protein of approximately 50 kD as part of the proteasome activator PA700, that is the substrate-recognizing and unfolding unit of the 26S proteasome. These results indicate that both the 20S core protease as well as the proteasome activator PA700 are targets of modulatory subunit replacements or transient association of regulatory components in the course of microglial activation.


Subject(s)
Cysteine Endopeptidases/chemistry , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Microglia/immunology , Multienzyme Complexes/chemistry , Adenosine Triphosphatases/metabolism , Animals , Antigen Presentation , Antioxidants/pharmacology , Ascorbic Acid/pharmacology , Cells, Cultured , Cysteine Endopeptidases/drug effects , Cysteine Endopeptidases/ultrastructure , Electrophoresis, Gel, Two-Dimensional , Interleukin-6/metabolism , Mice , Mice, Inbred Strains , Microglia/metabolism , Multienzyme Complexes/drug effects , Multienzyme Complexes/ultrastructure , Phenotype , Precipitin Tests , Proteasome Endopeptidase Complex , Tumor Necrosis Factor-alpha/metabolism
10.
J Neuropathol Exp Neurol ; 58(10): 1078-89, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10515231

ABSTRACT

Gram-positive Streptococcus pneumoniae is the major pathogen causing lethal meningitis in adults. We used pneumococcal cell walls (PCW) to investigate microglial consequences of a bacterial challenge and to determine the role of serum in the activation process. PCW caused the characteristic induction of an outwardly rectifying K+ channel (IK+(OR)), together with a concomitant suppression of the constitutively expressed inward rectifier K+ current, and evoked the release of tumor necrosis factor-alpha (TNF alpha), interleukin-6 (IL-6), IL-12, KC, macrophage inflammatory protein (MIP) 1alpha and MIP-2. Serum presence strongly facilitated the PCW effects, similarly as observed for lipopolysaccharide (LPS) from gram-negative Escherichia coli. The inflammatory cytokine, interferon-gamma (IFNgamma) induced the same electrophysiological changes, but independent of serum. Recombinant LPS binding protein (LBP) could partially replace serum activity in LPS stimulations. In contrast, neither LBP nor an antibody-mediated blockade of the LPS receptor, CD14 had significant influences on PCW-inducible changes. Cell surface interactions and cofactor involvement in microglial activation by gram-positive bacteria are thus distinct from the mechanisms employed by LPS. Moreover, tyrphostin AG126, a protein kinase inhibitor that prevents activation of the mitogen-activated protein kinase, p42MAPK (ERK2), potently blocked the PCW-stimulated cytokine release while having only a limited effect on LPS-inducible cytokines. In contrast, AG126 did not influence IK+(OR) inductions. This indicates that PCW recruits more than 1 intracellular signaling pathway to trigger the various responses and that different bacterial agents signal through both common and individual routes during microglial activation.


Subject(s)
Acute-Phase Proteins , Gram-Negative Bacteria/physiology , Gram-Positive Bacteria/physiology , Membrane Glycoproteins , Microglia/microbiology , Microglia/physiology , Animals , Animals, Newborn/metabolism , Blood Physiological Phenomena , Carrier Proteins/pharmacology , Cell Wall/physiology , Cells, Cultured , Cytokines/metabolism , Drug Synergism , Embryo, Mammalian/cytology , Embryo, Mammalian/metabolism , Interferon-gamma/pharmacology , Ion Channels/metabolism , Lipopolysaccharides/pharmacology , Mice , Microglia/drug effects , Microglia/metabolism , Potassium Channels/drug effects , Potassium Channels/metabolism , Protein Kinases/physiology , Recombinant Proteins , Streptococcus pneumoniae/physiology
11.
Trends Neurosci ; 22(7): 290-5, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10370249

ABSTRACT

A wide heterogeneity in dendritic-spine morphology is observed and ultrastructural changes can be induced following experimental stimulation of neurons. Morphological adaptation of a given spine might, thus, reflect its history or the current state of synaptic activity. These changes could conceivably result from rearrangements of the cytoskeleton that is subjacent to excitatory synapses. This article dicusses the direct and indirect interactions, between glutamate receptors and the cytoskeletal proteins, which include PDZ-containing proteins, actin and tubulin, as well as associated proteins. In fact, the synaptic-activity-controlled balancing of monomeric, dimeric and polymeric forms of actin and tubulin might underlie the changes in spine shape. These continuous adaptations could be relevant for physiological events, such as learning and the formation of memory.


Subject(s)
Cytoskeletal Proteins/metabolism , Cytoskeleton/metabolism , Dendrites/metabolism , Nerve Tissue Proteins/metabolism , Receptors, Glutamate/metabolism , Actin Cytoskeleton/metabolism , Actins/metabolism , Animals , Cytoskeleton/ultrastructure , Dendrites/ultrastructure , Humans , Tubulin/metabolism
12.
Neuroscience ; 89(4): 1379-90, 1999.
Article in English | MEDLINE | ID: mdl-10362322

ABSTRACT

Lipopolysaccharides derived from cell walls of Gram-negative bacteria have proven a useful tool to simulate bacterial infection of the central nervous system. Rapid activation of microglia within the brain parenchyma as well as in vitro has thereby been shown to be an early event upon bacterial or lipopolysaccharide challenges. Less is known about microglial responses to a contact with Gram-positive bacteria, such as Streptococcus pneumoniae, a lethal pathogen causing meningitis with a 30% mortality rate. In the present study, we compared lipopolysaccharide-induced microglial activation in vitro with that induced by preparations of pneumococcal cell walls. As a readout of microglial activation, we studied by patch-clamp recording the expression of outward rectifying potassium currents (IK+OR), which are known to be induced by lipopolysaccharide. We found that pneumococcal cell walls and lipopolysaccharide induced a similar type of IK+OR. Stimulation of IK+OR by pneumococcal cell walls and lipopolysaccharide involved protein synthesis since it was not induced in the presence of cycloheximide. Pharmacological characterization of the pneumococcal cell wall- and lipopolysaccharide-induced currents with specific ion channel blockers indicated for both cases expression of the charybdotoxin/margatoxin-sensitive Kv1.3 subtype of the Shaker family of voltage-dependent potassium channels. Activation of the outward currents by pneumococcal cell walls depended on the developmental stage: while lipopolysaccharide triggered IK+OR in both embryonal and postnatal microglial cells, pneumococcal cell walls had only a marginal effect on embryonal cells. This, however, does not imply that embryonic microglial cells are unresponsive to pneumococcal cell walls. In both embryonic and postnatal cells, (i) the amplitude of the constitutively expressed inward rectifying potassium current was significantly reduced, (ii) tumor necrosis factor-a was released and (iii) the cells changed their morphology, similarly as it was induced by lipopolysaccharide treatment. Thus, embryonic microglial cells are sensitive to pneumococcal cell wall challenges, but respond with a distinctly different pattern of physiological reactions. The expression of IK+OR could thus be a suitable tool to study signalling cascades selectively involved in the activation of microglia by Gram-negative and -positive cell wall components and to functionally distinguish between populations of microglial cells.


Subject(s)
Brain/physiology , Cell Wall/immunology , Microglia/physiology , Potassium Channels, Tandem Pore Domain , Potassium Channels, Voltage-Gated , Potassium Channels/biosynthesis , Streptococcus pneumoniae/immunology , Animals , Animals, Newborn , Apamin/pharmacology , Brain/cytology , Brain/immunology , Cells, Cultured , Charybdotoxin/pharmacology , Elapid Venoms/pharmacology , Embryo, Mammalian , Kv1.3 Potassium Channel , Lipopolysaccharides/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Mice, Inbred Strains , Microglia/cytology , Microglia/immunology , Neurotoxins/pharmacology , Potassium Channel Blockers , Potassium Channels/physiology , Rats , Scorpion Venoms , Shaker Superfamily of Potassium Channels
13.
J Neurochem ; 72(5): 2215-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10217305

ABSTRACT

Interleukin (IL)-18 (interferon-gamma-inducing factor or IL-1gamma) belongs structurally to the IL-1 cytokine family and shares biological properties with IL-12. Expression, intracellular signaling, and functional relevance of IL-18 within the CNS are mostly unknown. We show that IL-18 protein is synthesized within mouse brain, preferentially during early postnatal stages, and that microglial cells but not astrocytes are a potential source. IL-18 is produced by cultured microglia on exposure to lipopolysaccharide (LPS). Microglia also express major components of the IL-1/IL-18 receptor system. On IL-18 stimulation, microglial IL-1 receptor-associated kinase (IRAK) can be coprecipitated with tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) but not with IL-1 receptor type I, indicating that IRAK recruits TRAF6 during IL-18 signaling. IL-18 inhibits the LPS-induced release of IL-12 and attenuates that of TNF-alpha, whereas the production of IL-6 and macrophage inflammatory protein-1alpha is only marginally affected. IL-18 may play a role during CNS development and can be produced by activated microglia, thus probably contributing to immune and inflammatory processes in the brain.


Subject(s)
Interleukin-18/metabolism , Interleukin-18/pharmacology , Microglia/drug effects , Microglia/metabolism , Aging/metabolism , Animals , Brain/cytology , Brain/metabolism , Cells, Cultured , Cytokines/metabolism , Interleukin-1 Receptor-Associated Kinases , Lipopolysaccharides/pharmacology , Mice , Protein Kinases/metabolism , Proteins/metabolism , Recombinant Proteins , TNF Receptor-Associated Factor 6
14.
Brain Res Mol Brain Res ; 63(1): 155-62, 1998 Dec 10.
Article in English | MEDLINE | ID: mdl-9838089

ABSTRACT

IL-15 is a pleiotropic cytokine modulating growth and differentiation of several hematopoietic cell types. Recently, we have demonstrated that mouse microglial cells, the brain macrophages, express both IL-15 and IL-15/IL-2 receptors. Based on single-cell RT-PCR data, we describe here an alternatively spliced IL-15 mRNA variant found in a small subpopulation of mouse microglia (5%, 3 out of 60 cells expressing IL-15 transcripts). PCR cycle sequencing of this larger transcript revealed the mouse homologue of the alternatively spliced exon A as it is known from the human IL-15 gene. Analysis of the corresponding mouse IL-15 gene region shows that the larger IL-15 transcript contains an yet unidentified 5' sequence of exon 5 while the shorter transcript uses an internal splice acceptor site. The mouse exon 5A segment has a length of 136 nt (17 nt longer than the human exon A). It contains five in-frame stop codons at its 5' end and a new translation initiation site at its 3' end. This new start site is surrounded by a favourable Kozak consensus sequence suggesting a more efficient translation rate. Further translational control by stem-loop binding factors is inferred by a predicted RNA stem-loop structure around the start site. Insertion of exon 5A would lead to an IL-15 polypeptide with a shortened leader sequence of 26 amino acids, as compared to the 48 amino acid leader sequence encoded by the transcript lacking exon 5A. Thus, the final IL-15 protein of the two splice variants is identical; different leader sequences could, however, lead to differences in the intracellular sorting, processing and/or secretion of IL-15.


Subject(s)
Alternative Splicing/physiology , Brain Chemistry/genetics , Exons/genetics , Interleukin-15/genetics , Microglia/physiology , Animals , Animals, Newborn , Base Sequence , Cerebral Cortex/cytology , Codon, Initiator/genetics , Consensus Sequence , Macrophages/physiology , Mice , Molecular Sequence Data , Nucleic Acid Conformation , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Transcription, Genetic/physiology
15.
Neuroscience ; 86(2): 627-34, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9881875

ABSTRACT

Although tumour necrosis factor alpha is said to play a key role in bacterial meningitis and other CNS diseases, the effects of this pro-inflammatory cytokine have only been studied in part and are incompletely understood. In a rat model, we investigated the effect of intracisternal injection of recombinant rat-specific tumour necrosis factor alpha (5, 35, 70 and 280 microg tumour necrosis factor alpha) (i) alone, (ii) combined with pneumococcal cell wall components, on regional cerebral blood flow, intracranial pressure, white blood cell count in the cerebrospinal fluid, and brain water content. Tumour necrosis factor a dose-dependently caused an increase in regional cerebral blood flow (up to 221 +/- 43% of baseline values) over the six hour observation period and mild cerebrospinal fluid leukocytosis; intracranial pressure and brain water content were unchanged. Hypothesizing that regional cerebral blood flow changes are dependent on nitric oxide, tumour necrosis factor alpha-induced regional cerebral blood flow increase was abolished by Aminoguanidine, a selective inhibitor of inducible nitric oxide synthase. Combination of the lowest tumour necrosis factor alpha dose and a low dose pneumococcal cell wall preparation magnified the inflammatory effect of both. We conclude that intrathecally injected tumour necrosis factor alpha alone results in only minor inflammatory changes, whereas it dramatically augments experimental meningitis.


Subject(s)
Brain/physiopathology , Inflammation/physiopathology , Meningitis, Pneumococcal/physiopathology , Tumor Necrosis Factor-alpha/pharmacology , Animals , Body Water/metabolism , Brain/blood supply , Brain/drug effects , Cell Wall , Cerebrovascular Circulation/drug effects , Dose-Response Relationship, Drug , Guanidines/pharmacology , Intracranial Pressure/drug effects , Intracranial Pressure/physiology , Leukocyte Count , Male , Rats , Rats, Wistar , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Regional Blood Flow/drug effects , Streptococcus pneumoniae , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/physiology
16.
J Biol Chem ; 272(46): 28853-60, 1997 Nov 14.
Article in English | MEDLINE | ID: mdl-9360952

ABSTRACT

The cytokine, interleukin (IL)-15, and the T cell growth factor, IL-2, exhibit a similar spectrum of immune effects and share the IL-2 receptor (IL-2R) subunits IL-2Rbeta and IL-2Rgamma for signaling in hematopoietic cells. Numerous neuroregulatory activities of IL-2 have been suggested, but its expression in the normal central nervous system (CNS) is apparently very low and regionally restricted. We show by RNA and protein detection that IL-15, its specific receptor molecule, IL-15Ralpha, and the signal-transducing receptor subunits, IL-2Rbeta and IL-2Rgamma, are constitutively present in various regions of the developing and adult mouse brain. We further demonstrate, also at the single-cell level, that IL-15 and the components for IL-15Ralpha/IL-2Rbetagamma receptors are expressed by microglia. Tyrosine phosphorylation data are presented showing that IL-15 signaling in microglia involves Janus kinase 1 activity. At doses of 0.1-10 ng/ml, IL-15 affected functional properties of these cells, such as the production of nitric oxide, and supported their growth in culture, suggestive of a role as an autocrine growth factor. Microglial IL-15 could thus play a pivotal role in the CNS and may participate in certain CNS and neuroendocrine functions previously ascribed to IL-2.


Subject(s)
Brain/metabolism , Interleukin-15/metabolism , Microglia/metabolism , Protein-Tyrosine Kinases/metabolism , Receptors, Interleukin-2/metabolism , Animals , Calcium/metabolism , Cells, Cultured , Humans , Interleukin-15/genetics , Janus Kinase 1 , Mice , Nitric Oxide/biosynthesis , Phosphorylation , Polymerase Chain Reaction , Protein Binding , RNA, Messenger/genetics , Rats , Rats, Wistar , Receptors, Interleukin-15 , Receptors, Interleukin-2/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Signal Transduction
17.
Neurosci Biobehav Rev ; 21(5): 649-78, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9353797

ABSTRACT

Calcitonin generelated peptide (CGRP) is a neuropeptide discovered by a molecular approach over 10 years ago. More recently, islet amyloid polypeptide or amylin, and adrenomedullin were isolated from human insulinoma and pheochromocytoma respectively, and revealed between 25 and 50% sequence homology with CGRP. This review discusses findings on the anatomical distributions of CGRP mRNA, CGRP-like immunoreactivity and receptors in the central nervous system, as well as the potential physiological roles for CGRP. The anatomical distribution and biological activities of amylin and adrenomedullin are also presented. Based upon the differential biological activity of various CGRP analogs, the CGRP receptors have been classified in two major classes, namely the CGRP1 and CGRP2 subtypes. A third subtype has also been proposed (e.g. in the nucleus accumbens) as it does not share the pharmacological properties of the other two classes. The anatomical distribution and the pharmacological characteristics of amylin binding sites in the rat brain are different from those reported for CGRP but share several similarities with the salmon calcitonin receptors. The receptors identified thus far for CGRP and related peptides belong to the G protein-coupled receptor superfamily. Indeed, modulation of adenylate cyclase activity following receptor activation has been reported for CGRP, amylin and adrenomedullin. Furthermore, the binding affinity of CGRP and related peptides is modulated by nucleotides such as GTP. The cloning of various calcitonin and most recently of CGRP1 and adrenomedullin receptors was reported and revealed structural similarities but also significant differences to other members of the G protein-coupled receptors. They may thus form a new subfamily. The cloning of the amylin receptor(s) as well as of the other putative CGRP receptor subtype(s) are still awaited. Finally, a broad variety of biological activities has been described for CGRP-like peptides. These include vasodilation, nociception, glucose uptake and the stimulation of glycolysis in skeletal muscles. These effects may thus suggest their potential role and therapeutic applications in migraine, subarachnoid haemorrhage, diabetes and pain-related mechanisms, among other disorders.


Subject(s)
Calcitonin Gene-Related Peptide/physiology , Nervous System Physiological Phenomena , Nervous System/anatomy & histology , Receptors, Calcitonin Gene-Related Peptide/physiology , Amino Acid Sequence , Animals , Humans , Molecular Sequence Data , Rats , Receptors, Calcitonin Gene-Related Peptide/drug effects
18.
Neuroscience ; 79(3): 799-818, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9219943

ABSTRACT

Interleukin-2 is an immunoregulatory cytokine with several recently established CNS activities. Central effects of interleukin-2 include growth promotion for neuronal and glial cells as well as modulatory influences on neurotransmission and hormone release. However, little is known about the consequences in the CNS of chronically elevated levels of interleukin-2. Alterations in the interleukin-2/interleukin-2 receptor system are not only associated with CNS trauma, inflammation and certain neuropathologies; elevated interleukin-2 concentrations are especially induced during the therapeutic use of interleukin-2 in cancer treatments. In the present study, intracerebroventricular (i.c.v.) interleukin-2 infusions (5 15 U/h) were performed in Sprague Dawley rats for up to 14 days. Interleukin-2-treated animals showed significantly increased plasma levels of corticosterone indicating an hyperfunctioning of the hypothalamic-pituitary-adrenocortical axis that lasted over the 14 day infusion period. Moreover, the performance of interleukin-2-treated animals in the Morris swim maze task was transiently impaired. Quantitative receptor autoradiographic analyses revealed changes in the binding levels of cholinergic M1 and M2 as well as dopaminergic D1 and D2 receptors in selected brain areas in which interleukin-2 was shown to modulate neurotransmission and which are enriched with interleukin-2 receptor expression. Decreased receptor binding levels were observed in the frontoparietal cortex (M2, D1, D2), hippocampal CA1 region (M1, M2) and the nucleus accumbens (D2). Histological and immunohistochemical examination of the brains of interleukin-2-treated animals revealed multiple alterations. Interleukin-2 treatment resulted in an intracranial accumulation of non-neural, MHC class II-positive cells as well as T and B lymphocytes within the infused brain hemisphere. Cellular infiltrates were associated with angiogenesis and the deposition of extracellular matrix material, such as fibronectin. Adjacent brain regions that were partly invaded and dislodged by the cellular masses were characterized by reactive astrogliosis, microglial activation, endothelial upregulation of adhesion molecules, myelin damage and neuronal loss. Together the data suggest that persistently elevated central levels of interleukin-2 can interfere with several CNS functions and may lead to nervous tissue injury. These findings could be relevant to CNS pathologies characterized by abnormal interleukin-2 production and to central responses to interleukin-2 treatments.


Subject(s)
Brain/drug effects , Interleukin-2/toxicity , Animals , Autoradiography , Brain/ultrastructure , Injections, Intraventricular , Male , Microscopy, Confocal , Rats , Rats, Sprague-Dawley , Time Factors
19.
Neuroreport ; 7(18): 2883-8, 1996 Nov 25.
Article in English | MEDLINE | ID: mdl-9116202

ABSTRACT

Intracerebroventricular infusion of interleukin-2 (IL-2, 15 U h-1 for 14 days) chronically activated the hypothalamic-pituitary-adrenocortical (HPA) axis in rats. IL-2 induced increases in plasma levels of adrenocorticotropic hormone (ACTH, up to two-fold) and corticosterone (up to four-fold) compared with controls. Continuously elevated brain levels of IL-2 did not lead to a persistent HPA activation, but resulted in (two) periods of hormonal hypersecretion. ACTH and corticosterone levels were elevated between days 3 and 5, with changes in corticosterone preceding those of ACTH. Concentrations of corticosterone, but not of ACTH, increased again on day 11. Underscoring its importance as a neuroendocrine regulator, this study reveals that, in addition to its immediate effects, IL-2 induces a complex pattern of chronic HPA stimulation. These findings may functionally relate to several CNS disorders and certain endocrine dysfunctions observed during IL-2 immunotherapy.


Subject(s)
Hypothalamo-Hypophyseal System/physiology , Interleukin-2/pharmacology , Adrenocorticotropic Hormone/blood , Animals , Corticosterone/blood , Histocytochemistry , Hypothalamo-Hypophyseal System/drug effects , Injections, Intraventricular , Interleukin-2/administration & dosage , Male , Radioimmunoassay , Rats , Rats, Sprague-Dawley
20.
Synapse ; 24(2): 104-14, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8890452

ABSTRACT

Interleukin-2 (IL-2), a key regulator of immune functions, also has potent effects on neurons and glia. IL-2 modulates neural cell growth and survival and transmitter and hormone releases and is thought to mediate neuroimmune interactions. Investigating the neuroendocrine consequences of chronically elevated central nervous system (CNS) levels of IL-2, we recently observed marked neurotoxicity [Hanisch et al. (1994) Endocrinology 135:2465-2472]. In the present study, we characterize in detail the modifications in brain tissue architecture as they result in Sprague-Dawley rats from intracerebroventricular (i.c.v.) administration of low amounts of IL-2 (5 and 15 U/h, respectively, delivered by means of osmotic minipumps for up to 14 days). Histological inspection of the brains revealed massive cellular infiltrates in the ipsilateral hemisphere. The infiltrates were associated with pronounced angiogenesis and changes in the composition of the extracellular matrix. These anatomical changes apparently developed between day 7 and 14. They were specific for IL-2 and were not seen in animals treated, for example, with heat-inactivated IL-2 (controls). We further show that chronic central administration of IL-2 let to T and B lymphocyte invasion of the brain and an intracranial agglomeration of large numbers of MHC class II-positive cells. Immunocytochemistry revealed a widespread inundation of CNS tissue and a decoration of glial cells and neurons by endogenous antibodies. Tissue regions around the IL-2-induced infiltrates showed myelin destruction and neuronal cell loss. Chronically elevated CNS levels of IL-2 may, thus, not only interfere with neurotransmission and endocrine functions but also severely disturb tissue homeostasis. Therefore, the present findings could be relevant to brain injuries, CNS disorders, and clinical treatments associated with increased IL-2 levels or involving an immune component.


Subject(s)
B-Lymphocytes/ultrastructure , Brain/drug effects , Interleukin-2/toxicity , Neurons/drug effects , Plasma Cells/ultrastructure , T-Lymphocytes/ultrastructure , Animals , Immunohistochemistry , Male , Microscopy, Electron , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...